| Systematic (IUPAC) name | |
|---|---|
| 4-[(2R,3S)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol | |
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy cat. | B (US) |
| Legal status | ? |
| Routes | Topical |
| Pharmacokinetic data | |
| Bioavailability | Very low |
| Identifiers | |
| CAS number | 500-38-9 |
| ATC code | L01XX10 |
| PubChem | CID 71398 |
| DrugBank | DB00179 |
| ChemSpider | 64490 |
| UNII | 7BO8G1BYQU |
| ChEMBL | CHEMBL313972 |
| Chemical data | |
| Formula | C18H22O4 |
| Mol. mass | 302.365 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Masoprocol is an antineoplastic drug used to treat skin growths caused by sun exposure. A form of nordihydroguaiaretic acid that is taken by mouth is being studied in the treatment of prostate cancer.
Also called nordihydroguaiaretic acid, NDGA, and actinex.
Nordihydroguaiaretic acid is an antioxidant, and it may block certain enzymes needed for tumor growth.
It is a lipoxygenase inhibitor.[1]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)